DRUG FLURENISID AS AN IMMUNOMODULATOR FOR THE TREATMENT OF ORPHAN DISEASES

DRUG FLURENISID AS AN IMMUNOMODULATOR FOR THE TREATMENT OF ORPHAN DISEASES

Flurenizide was created as a result of purposeful synthesis of fl uorene series compounds and research into their chemical, physical, biological and pharmacological characteristics. The study was directed at converting low-molecular chemical compounds into medication according to the following schem...

Full description

Bibliographic Details
Main Author:	Мaria Kovalenko
Format:	Article
Language:	English
Published:	Shevchenko Scientific Society 2017-12-01
Series:	Праці Наукового товариства імені Шевченка. Медичні науки
Subjects:	medicinal product (drug), fl uorenic, viral infections, rare (orphan ) diseases
Online Access:	https://mspsss.org.ua/index.php/journal/article/view/109

Similar Items

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-11-01)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
by: Kavisha Jayasundara, et al.
Published: (2019-01-01)

Orphan drugs for the pathogenetic treatment of rаre diseases in the drug registry
by: S. A. Mishinova
Published: (2019-04-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
by: Viviana Giannuzzi, et al.
Published: (2017-04-01)

An analysis of orphan medicine expenditure in Europe: is it sustainable?
by: Jorge Mestre-Ferrandiz, et al.
Published: (2019-12-01)

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
by: Kathleen L. Miller, et al.
Published: (2021-06-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01)

Orphan drug: Development trends and strategies
by: Aarti Sharma, et al.
Published: (2010-01-01)

Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01)

Evaluating health policy and legal responses : how to reduce barriers and improve access to orphan drugs for rare diseases in Canada
by: Blais, Catherine-Marie
Published: (2016)

A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01)

EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES REGARDING RARE DISEASES AND ORPHAN DRUGS
by: Dušanka Krajnović, et al.
Published: (2013-01-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
by: Kathleen L. Miller, et al.
Published: (2020-09-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01)

Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review
by: Kacetl J, et al.
Published: (2020-10-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)

European and Italian regulation on orphan medicinal products
by: Roberta Joppi
Published: (2013-03-01)

Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis
by: Konstantin Mechler, et al.
Published: (2020-03-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
by: Adkins EM, et al.
Published: (2017-06-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
by: Liz Morrell, et al.
Published: (2017-08-01)

Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review
by: Andrea Young, et al.
Published: (2017-12-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01)

Investigating the landscape of US orphan product approvals
by: Kathleen L. Miller, et al.
Published: (2018-10-01)

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review
by: Balijepalli C, et al.
Published: (2020-08-01)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
by: Kim Hendrickx, et al.
Published: (2021-09-01)

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
by: Aleksandra Baran-Kooiker, et al.
Published: (2018-10-01)

From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue
by: Marialuisa Saviano, et al.
Published: (2019-03-01)

Examining Why the Canadian Federal Government Placed an Orphan Drug Strategy on Their Decision Agenda Now
by: Mark Gary Embrett
Published: (2014-02-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
by: Fernando de Andrés-Nogales, et al.
Published: (2021-04-01)

A Multi Criteria Approach for The Assessment of Drugs for Rare Diseases
by: Naili, Abdallah
Published: (2016)

The problem of rare (orphan) diseases in the Russian Federation: Medical and normative legal aspects of its solution
by: P V Novikov
Published: (2014-12-01)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
by: Mondher Toumi, et al.
Published: (2020-07-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Public spending on orphan medicines: a review of the literature
by: Margit Gombocz, et al.
Published: (2020-10-01)